Comments
Sun Pharma has made a milestone payment of $10 million to Sun Pharma Advanced Research Company as royalty for Xelprostm. Sun Pharma had earlier said it had received US FDA approval for Xelprostm, which is indicated for the treatment of open-angle glaucoma or ocular hypertension. Sun Pharma, which had in-licensed Xelprostm from Sun Pharma Advanced Research Company in 2015, has commercialised the product. The royalty payment is linked to sales.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.